Volume | 357,080 |
|
|||||
News | - | ||||||
Day High | 11.41 | Low High |
|||||
Day Low | 11.17 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Dynavax Technologies Corp | DVAX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.41 | 11.17 | 11.41 | 11.42 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,119 | 357,080 | $ 11.28 | $ 4,027,059 | - | 10.06 - 15.15 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
11:06:04 | 5 | $ 11.23 | USD |
Dynavax Technologies Corp Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.46B | 130.61M | - | 232.28M | -6.39M | -0.05 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Dynavax Technologies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DVAX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.32 | 12.08 | 11.17 | 11.71 | 3,385,794 | -0.095 | -0.84% |
1 Month | 12.41 | 12.67 | 11.17 | 11.86 | 2,101,512 | -1.19 | -9.55% |
3 Months | 12.91 | 13.265 | 11.17 | 12.29 | 1,968,985 | -1.69 | -13.05% |
6 Months | 14.15 | 15.15 | 11.17 | 13.06 | 1,879,914 | -2.93 | -20.67% |
1 Year | 10.88 | 15.15 | 10.06 | 13.19 | 1,744,421 | 0.345 | 3.17% |
3 Years | 9.66 | 21.39 | 7.09 | 12.96 | 2,180,387 | 1.57 | 16.20% |
5 Years | 6.55 | 21.39 | 1.80 | 9.82 | 2,623,388 | 4.68 | 71.37% |
Dynavax Technologies Description
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product. |